ReviewJBMR plus2025
Osteitis fibrosa cystica recovery following parathyroidectomy for primary hyperparathyroidism: a case series and review of literature.
Review in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biochemical Predictors and Clinical Characteristics for the Development of Cytopenia and Bone Marrow Involvement Among Patients With Primary Hyperparathyroidism.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteitis fibrosa cystica (OFC) is an extreme manifestation of accelerated bone resorption in primary hyperparathyroidism (PHPT), rarely encountered nowadays. Bone mineral density gain following parathyroidectomy (PTx) is well documented, while little is known regarding the timeline of lytic lesions remineralization and recovery. We present three patients with OFC, surgically treated for PHPT, with clinical, biochemical, and advanced radiological (CT or MRI) post-PTx follow-up. Additionally, we review published OFC case reports that include serial imaging of bony lesions following PTx. All patients received calcium, magnesium and alphacalcidiol supplementation post-PTx with serum calcium, PTH, and alkaline phosphatase gradually normalizing. Patients 1 and 2 exhibited an impressive remineralization of pelvic lytic lesions within 6 and 12 mo following PTx, respectively. Patient 3 showed partial remineralization of C4-C5 vertebrae at 6 mo, with continued improvement at 18 mo post-PTx. Both Patients 1 and 3 required salvage orthopedic intervention. We summarize reports of 54 patients with PHPT and OFC, assessed for lytic lesion recovery after PTx using various imaging modalities. Most lesions showed partial remineralization within 6-12 mo. Near full and complete remineralization was evident in 38 (70.3%) of the patients on the last imaging follow-up. Substantial remineralization of lytic lesions in OFC can be observed within months of PTx, even in large or symptomatic lesions. This early skeletal recovery may obviate the need for orthopedic intervention in selected patients and supports a conservative management approach when lesion location permits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.